Cardiovascular diseases (CVD) are increasing in epidemic proportions in developing countries. CVD already accounts for almost 10 percent of the developing world's burden of disease and is likely to become the developing world's leading cause of death. There is reason for hope, however, given that huge potential exists for applying R&D to control this emerging epidemicboth in creating powerful new interventions such as vaccines and dietary supplements and in guiding behavior. In addition, a considerable body of evidence suggests that current risk-factor prevention programs and low-cost case management of CVD offer feasible, cost-effective ways to reduce CVD mortality and disability in developing country populations. Large-scale CVD control efforts are lacking, however, and thus governments and individuals are left to make choices about health and health care services without the benefit of appropriate knowledge. This report was designed to promote a policy dialogue on CVD based on informed knowledge of R&D opportunities that offer effective, affordable, and widely applicable responses in developing countries. The report examines (a) the emerging burden of CVD in developing countries, (b) the future worldwide burden of CVD, (c) current prevention and treatment of CVD in developing countries, (d) R&D to support CVD control, (e) opportunities and priorities for R&D, and the need for institutional arrangements for collaboration in facing the epidemic.
Table of Contents
Front Matter Contents Executive Summary 1 The Current Burden of Cardiovascular Diseases in Developing Countries 2 The Future Burden of Cardiovascular Diseases in Developing Countries 3 Prevention and Treatment of Cardiovascular Diseases in Developing Countries 4 Current Research and Development in Developing Countries 5 Priorities for Global Research and Development 6 Institutional Arrangements for Research and Development Epilogue References Appendix A: Five Steps for Setting Research Priorities Appendix B: Glossary of Cardiologic and Epidemiologic Terms
